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Received June 6, 2014; accepted February 9, 2015AbstractBackground: A large number of studies have hypothesized that Toxoplasma gondii is a potentially relevant etiological factor in some cases of
schizophrenia. By contrast, some studies have disproved this association. The aim of this study was to investigate whether latent toxoplasmosis
has any role in schizophrenia disease. Additionally, the association between T. gondii and subtypes of schizophrenia, and the impacts of
toxoplasmosis on psychopathology were examined in the study.
Methods: A total of 85 patients with schizophrenia and 60 healthy volunteers were included in this prospective study. Immunoglobulin G (IgG)
antibody to T. gondii was examined by enzyme-linked immune-sorbent assay method.
Results: Seropositivity rates were 43.5% for the patients with schizophrenia and 43.3% for the healthy controls (odds ratio: 1.008, 95% con-
fidence interval: 0.517e1.964, p ¼ 0.981).There was no significant difference in T. gondii IgG positivity between the schizophrenia and control
groups with respect to sex and age. The difference in seroprevalence of T. gondii IgG antibodies among the schizophrenia subtypes was not
statistically significant ( p ¼ 0.934). No significant difference was found in Positive and Negative Syndrome Subscales between Toxoplasma-
infected and Toxoplasma-free patients.
Conclusion: In the study area with a high prevalence of T. gondii, no association between toxoplasmosis and schizophrenia was detected. These
findings showed that toxoplasmosis has no role in the risk of schizophrenia disease.
Copyright © 2015 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Schizophrenia is a serious neuropsychiatric disorder that is
thought to have multiple etiologies. Family studies have
indicated that genetic factors have a key role in etiopatho-
genesis of schizophrenia.1 By contrast, epidemiologic studies
have indicated that environmental exposures, such as win-
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life.2 In researches on infectious agents, it has been hypothe-
sized that Toxoplasma gondii is a potentially relevant etio-
logical factor in some cases of schizophrenia.3e5
T. gondii that commonly infects humans and animals is an
obligate intracellular protozoan parasite. Humans are mainly
infected by consumption of undercooked meat containing
tissue cysts or by ingestion of food and water contaminated
with oocysts from infected cat feces. Furthermore, T. gondii
can be transmitted by maternofetal transmission that can cause
congenital toxoplasmosis, blood transfusion, and solid organ
or hematopoietic cell transplantation.6,7 After ingestion, spo-
rozoites and bradyzoites released from oocysts and cysts
invade intestinal cells and are converted to tachyzoites.8ociation. All rights reserved.
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seen in cells of different tissues in the acute phases of infec-
tion. Within weeks or months, tachyzoites disappear, and the
resting bradyzoites in tissue cysts appear in various tissues,
mainly in the brain and muscle.9,10 These cysts may remain
throughout the life of the host. If the host becomes immuno-
suppressed, the infection can be reactivated.11
Both in vitro neuropathologic studies of T. gondii in cell
cultures and postmortem studies on the brains of schizophrenic
patients have shown many glial abnormalities, especially in
astrocytes. The fact that patients with schizophrenia have
abnormal neurotransmitters, especially dopamine, glutamate,
and gamma aminobutyric acid (GABA), is well known. Animal
studies of T. gondii have demonstrated that this organism can
lead to altered behavior and affect dopamine, norepinephrine,
and other neurotransmitters.2,12 Recent studies have indicated
that the genome of T. gondii has two genes encoding tyrosine
hydroxylase; this enzyme affects dopamine biosynthesis.1
In the literature, there are numerous studies to indicate that
schizophrenia disease is associated with toxoplasmosis. How-
ever, some studies have disproved this association. This study
investigated whether latent toxoplasmosis has any role in
schizophrenia disease, by analyzing T. gondii immunoglobulin
G (IgG) antibodies. In addition, the association between
T. gondii and subtypes of schizophrenia, and the impacts of
toxoplasmosis on psychopathology were examined in the study.
2. Methods2.1. PatientsTable 1
Demographic characteristics of patients with schizophrenia and healthy
controls.
Characteristics Patients with
schizophrenia
n (%)
Healthy
controls
n (%)
p
Number of participants 85 60
Age (mean ± SD) 41.73 ± 12.07 40.45 ± 9.49 0.494
Sex Male 46 (54.1) 31 (51.7) 0.771
Female 39 (45.9) 29 (48.3)
Age group (y) <30 17 (20) 6 (10) 0.027
30e39 18 (21.2) 26 (43.3)
40e49 30 (35.3) 15 (25)
50 20 (23.5) 13 (21.7)
Cat contact history 50 (58.8) 8 (13.3) <0.001
Dog contact history 46 (54.1) 8 (13.3) <0.001This prospective studywas conducted inElazigMentalHealth
Hospital, Elazig, Turkey. A total of 85 patients with schizo-
phrenia and 60 healthy volunteers were included in the study.
Clinical diagnosis was confirmed through the Diagnostic and
Statistical Manual of Mental Disorders, DSM-IV-TR. The Posi-
tive and Negative Syndrome Scale is a medical scale, which is
used for measuring symptoms of patients with schizophrenia.
Patients with histories of head trauma, brain surgery, meningitis,
encephalitis, mental retardation, alcoholism, substance abuse,
and immunodeficiency disease were excluded from the study.
The control group consisted from 60 healthy volunteers
who had no history of schizophrenia or psychiatric disorder.
The healthy volunteers comprised health care workers who
shared the same environment and ate the same food as the
patients. A questionnaire was administered to all individuals
participating in the study, which included information on their
age, sex, medical history, family history, dietary habits
(especially about consuming uncooked/undercooked meat,
milk, or eggs), and close contact with cats or dogs up to the
participant's age of 15 years. This study was approved by the
Firat University Ethical Committee.Consumption of
uncooked meat, milk,
chicken eggs
64 (75.3) 21 (35) <0.0012.2. Serological analysis
Schizophrenia history
in family
10 (11.8) 0 0.006
SD ¼ standard deviation.
Blood samples were taken from all participants of this
study, under sterile conditions. The samples were centrifugedat 200g, and the sera were stored at 20C until serological
examination. The commercial enzyme-linked immune-sorbent
assay kits (Vircell, Granada, Spain) were used for detection of
T. gondii IgG. All samples were analyzed on the Triturus
system (Grıfols, Parets del Valles, Spain) according to the
manufacturer's instructions. T. gondii IgG was measured by the
semiquantitative ELISA method. A sample was considered
negative if T. gondii IgG level was under 10 IU/mL, and values
of above 10 IU/mL were also considered positive.2.3. Statistical analysisStatistical analyses were performed using SSPS version 21
(SPSS Inc., Chicago, IL, USA). Visual (histograms) and
analytical (KolmogoroveSimirnov/ShapiroeWilk's test)
methods were used to test the normality of distributions of
continuous variables. The Student t test or ManneWhitney U
test, where appropriate, was used to compare parameters be-
tween the groups. The Chi-square test or Fisher exact test,
where appropriate, was used for categorical comparisons of
nominal values in different groups. A p value <0.05 was
considered statistically significant.
3. Results
Demographic properties of the participants are summarized
in Table 1. There were no statistically significant differences
between patients with schizophrenia and controls with respect
to age and sex.
The seroprevalence of T. gondii IgG antibodies was
detected in 43.5% of patients with schizophrenia and 43.3% of
healthy controls. As shown in Table 2, there were no statisti-
cally significant differences in T. gondii IgG positivity
between the schizophrenia and control groups.
There were also no significant differences in T. gondii IgG
positivity between the schizophrenia and control groups with
Table 2
Seroprevalence of Toxoplasma gondii IgG antibodies in the study populations.
Patients with schizophrenia Healthy controls c2 p OR CI95
IgG positive, n (%) IgG negative, n (%) IgG positive, n (%) IgG negative, n (%)
Overall 37 (43.5) 48 (56.5) 26 (43.3) 34 (56.7) 0.001 0.981 1.008 0.517e1.964
Sex Male 19 (41.3) 27 (58.7) 13 (41.9) 18 (58.1) 0.003 0.956 0.974 0.387e2.454
Female 18 (46.2) 21 (53.8) 13 (44.8) 16 (55.2) 0.012 0.914 1.055 0.402e2.770
Age group (y) <30 5 (29.4) 12 (70.6) 1 (16.7) 5 (83.3) a >0.99 2.083 0.191e22.670
30e39 4 (22.2) 14 (77.8) 10 (38.5) 16 (61.5) 1.293 0.256 0.457 0.117e1.787
40e49 13 (43.3) 17 (56.7) 9 (60) 6 (40) 1.112 0.292 0.510 0.145e1.798
50 15 (75) 5 (25) 6 (46.2) 7 (53.8) a 0.142 3.500 0.791e15.495
CI ¼ confidence interval; IgG ¼ immunoglobulin G; OR ¼ odds ratio.
a Fisher's exact test was performed.
Table 4
PANSS subscales in Toxoplasma-infected and Toxoplasma-free patients.
PANSS T. gondii IgG
positive
Mean ± SD
T. gondii IgG
negative
Mean ± SD
p
Positive subscale score 17.60 ± 10.08 22.02 ± 13.23 0.136
Negative subscale score 29.82 ± 8.95 29.20 ± 8.68 0.753
General psychopathology
subscale score
36.88 ± 14.21 36.28 ± 14.61 0.907
PANSS 84.41 ± 22.64 87.50 ± 24.76 0.569
IgG ¼ immunoglobulin G; PANSS ¼ Positive and Negative Syndrome Scale;
SD ¼ standard deviation.
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in male and female patients with schizophrenia was 41.3% and
46.2%, respectively ( p ¼ 0.653). The participants were cate-
gorized into four groups based on their age, and no significant
differences in the seroprevalence of T. gondii were seen be-
tween the schizophrenia group and healthy controls with
respect to age groups (Table 2). However, the odds ratio (OR)
was detected to be 3.5 for participants aged >50 years.
In Table 3, the patients with schizophrenia were categorized
according to schizophrenia subtypes. The difference in the
seroprevalence of T. gondii IgG antibodies among schizo-
phrenia subtypes was not statistically significant.
The effect of toxoplasmosis on psychopathology was
investigated in patients with schizophrenia. No significant
difference was found in Positive and Negative SyndromeTable 3
Seroprevalence of Toxoplasma gondii IgG antibodies in the schizophrenia
subtypes.
Schizophrenia subtypes T. gondii IgG p
Positive Negative
Paranoid Count 15 16 0.934
% within schizophrenia
subtypes
48.4 51.6
% within T. gondii IgG 40.5 33.3
Disorganized Count 5 7
% within schizophrenia
subtypes
41.7 58.3
% within T. gondii IgG 13.5 14.6
Catatonic Count 0 1
% within schizophrenia
subtypes
0.0 100.0
% within T. gondii IgG 0.0 2.1
Undifferentiated Count 2 3
% within schizophrenia
subtypes
40.0 60.0
% within T. gondii IgG 5.4 6.3
Residual Count 10 15
% within schizophrenia
subtypes
40.0 60.0
% within T. gondii IgG 27.0 31.3
Simple schizophrenia Count 5 6
% within schizophrenia
subtypes
45.5 54.5
% within T. gondii IgG 13.5 12.5
IgG ¼ immunoglobulin G.Subscales between Toxoplasma-infected and Toxoplasma-free
patients (Table 4).
4. Discussion
In this prospective study, no significant difference was
found in the seroprevalence of T. gondii between patients with
schizophrenia and healthy controls (OR: 1.008, 95% confi-
dence interval: 0.517e1.964, p ¼ 0.981). Patients and control
individuals had the similar prevalence of toxoplasmosis. In
this region, raw meatball consumption and village life are
mostly common. Therefore, the prevalence of T. gondii anti-
bodies in the general population is high. The high seropreva-
lence in both the schizophrenia and the control group could be
due to the high prevalence of T. gondii in the general popu-
lation in Elazig. Therefore, the prevalence of T. gondii anti-
bodies in the patients with schizophrenia in this study may be
less apparent. These results were consistent with some studies.
Tanyu¨ksel et al13 from Ankara, Turkey, did not find any sig-
nificant differences in seropositivity to T. gondii between pa-
tients with the first episode of schizophrenia and control
individuals. In another study published in 2014, anti-Toxo-
plasma antibodies were detected in 34% of patients with
schizophrenia and 47.39% of healthy controls.14
The findings of the present study have shown inconsistency
with other studies that have reported that seropositivity to
T. gondii infection was significantly higher in patients with
schizophrenia compared with that in healthy controls. The re-
sults of the study that was carried out by Çetinkaya et al9 in the
same hospital in Elazig in 2007 are noteworthy. The authors
found that the seropositivity rate for T. gondii IgG antibodies in
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that in healthy volunteers (22%) or patients with depressive
disorder (24%). However, in this area, the prevalence of T.
gondii antibodies in the general population is higher. Several
studies have evaluated the prevalence of T. gondii antibodies in
the general population in Elazig. In a study, the prevalence of T.
gondii was 41%, whereas in another study it was found to be
31%.15,16 Additionally, the seropositivity rate of the healthy
group in the present study was 43.3%. The seropositivity rates
in these studies were higher than that for healthy controls in the
study conducted by Çetinkaya et al.9 Yuksel et al2 from Istan-
bul, Turkey, found that T. gondii seropositivity rate was 61% in
patients with schizophrenia, 37% in patients with anxiety and
depression, and 45% in healthy controls. The authors have
suggested that toxoplasmosis does not have a direct effect on
the risk of schizophrenia in Turkey.
Male and female patients with schizophrenia did not show
any significant differences in the T. gondii IgG positivity rate.
Similar results were also reported in numerous studies.2,17 By
contrast, higher seropositivity in schizophrenic women than in
schizophrenic man was also indicated by Khademvatan et al.14
In the present study, seroprevalence of T. gondii was not
significantly different between the schizophrenia group and
healthy controls with respect to age groups. However, the OR
was detected as 3.5 in the >50-year age group. Similarly, in
the study of Yuksel et al2 for the 51e65-year age group, anti-
Toxoplasma IgG was significantly more prevalent in the
schizophrenia group compared with healthy controls (OR:
3.08). The authors have interpreted that the age range of
51e65 years was a risk factor.
Regarding the subtypes of schizophrenia, in this study, no
association between toxoplasmosis and subtypes of schizo-
phrenia was determined. Similarly, another study also reported
that there was no statistically significant difference in the preva-
lence of toxoplasmosis among subtypes of schizophrenia.14
Positive symptoms reflect an excess or distortion of the
individual's normal functions, are not present in people in the
normal population, and are mainly present during the acute
stage of schizophrenia. Negative symptoms are characterized
by the elimination or absence of normal behavior, and may
appear months and years before the onset of positive symp-
toms.18 Holub et al19 indicated that schizophrenic psychopa-
thology correlated negatively with the concentration of
T. gondii IgG antibodies in Toxoplasma-infected patients. In
addition, the authors have interpreted their findings as a cu-
mulative effect of latent toxoplasmosis on individual psycho-
pathology. Similar to the results of our study, Park et al17
found that there were no significant differences in positive
subscale, negative subscale, and general psychopathology
subscale scores between patients seronegative and seropositive
for T. gondii. For detecting a possible association between the
severity of symptoms and T. gondii further studies are needed.
Despite many studies having been conducted to reveal the
association between toxoplasmosis and schizophrenia, it is still
controversial whether T. gondii plays an etiological role in
schizophrenia disease. In geographic areas with a low preva-
lence of T. gondii antibodies, the higher prevalence of T. gondiiantibodies in patients with schizophrenia may be more apparent.
By contrast, in geographic areas with a high prevalence of T.
gondii antibodies, the increase in seropositivity of patients with
schizophrenia may be less apparent. Therefore, in areas with a
high prevalence of T. gondii, it would be difficult to reveal the
association between toxoplasmosis and schizophrenia. By
contrast, although the people of countries such as France, Brazil,
and Ethiopia have a high prevalence of T. gondii antibodies, the
prevalence of schizophrenia in these countries has not been re-
ported unusually high rates.1 In Turkey, the prevalence of
schizophrenia has been estimated to be as high as 8.9/1000.20
The main limitation of this study was the number of pa-
tients seropositive for T. gondii. Although there were 85 pa-
tients with schizophrenia in the study, the number of patients
seropositive for T. gondii (n ¼ 37) was small. Therefore, to
compare the clinical symptoms of seropositive and seronega-
tive schizophrenia patients further studies are need. Another
limitation was that the distribution of individuals across age
groups was not homogeneous.
In conclusion, in the study area with a high prevalence of
T. gondii, no association between toxoplasmosis and
schizophrenia was detected. In such areas, it is difficult to
establish whether T. gondii has an etiological role in
schizophrenia disease. To find out whether there is an asso-
ciation between toxoplasmosis and schizophrenia, more
studies should be conducted, especially in areas with a high
prevalence of T. gondii. Furthermore, future research should
determine the serotype of the prevailing strains of Toxo-
plasma in schizophrenic patients and general population, and
focus on the timing of infection.
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